GB Group PLC
16 December 2002
16 December 2002
GB Group plc
GB Announces Agreement With AstraZeneca for
Global Pharmaceutical Stock Data Analysis Project
GB Group plc today announces that it has signed an agreement with AstraZeneca to
provide software and service solutions which support the Company's global
inventory management system.
Under the agreement, which is worth an initial £0.2 million, GB Group will
supply an Alterian based solution package and its own tailored consultancy
service to AstraZeneca. The project has been established to help with the
analysis, reporting and the data management of its global pharmaceutical stocks
by country and to increase the speed of the flow of its data. By providing the
services under the agreement, AstraZeneca confidently expects to make
significant cash savings in the area of stock management.
Richard Law, GB Group's Chief Executive, said:
'I am delighted with our agreement with AstraZeneca. This is the first deal to
be closed from the pipeline of sales opportunities that GB Group acquired when
it bought eWare Interactive Limited on 1 November 2002 and I am confident that
more will follow. With the combination of eWare Interactive and GB Group's own
operations, we have established ourselves as a market-leader in data analytics
and we have demonstrated our ability to provide an effective solution to a
client's data issue and help improve processes and profitability.'
For further information, please contact:
GB Group plc 01244 657333
Richard Law, Chief Executive
Weber Shandwick Square Mile 020 7067 0700
Richard Hews
Christian San Jose
Website www.gb.co.uk
Notes for Editors:
1. GB Group plc is a listed company based in Chester. GB Group's
clients include Coral, De Vere Hotels, Bank of Ireland, npower, WHSmith - plus
many government agencies, such as HM Customs & Excise, National Criminal
Intelligence Service and the National Crime Squad. GB Group is a business
partner of Alterian plc.
2. AstraZeneca is one of the world's leading pharmaceutical companies.
Backed by a strong research base and extensive manufacturing and commercial
skills, it provides innovative, effective medicines that make a real difference
for patients in important areas of healthcare.
3. Alterian plc is a listed company based in Bristol. Alterian's
software solutions deliver sophisticated analysis across vast data sets,
handling complex queries at train-of-thought speed. Users gain actionable
insight on their operational data and receive a rapid return on their
investment. Alterian business partners take the software to construct a product
or service or deliver a tailored solution to their customers.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.